KALA BIO

204 articles about KALA BIO

• Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

  11/28/2022

  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for KPI-012 for the treatment of Persistent Corneal Epithelial Defect (PCED).

• Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/8/2022

  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

• Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

  11/1/2022

  Kala Pharmaceuticals, Inc. today announced the appointment of Marjan Farid, M.D., to its Board of Directors.

• Kala Pharmaceuticals Announces Reverse Stock SplitCommon Stock Will Begin Trading on Split-Adjusted Basis on October 21, 2022

  10/20/2022

  Kala Pharmaceuticals, Inc. today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares.

• Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

  9/6/2022

  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference.

• Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Aug 19, 2022

  8/19/2022

  Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

• Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

  8/18/2022

  Kala Pharmaceuticals, Inc. announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.001 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on August 29, 2022.

• Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/11/2022

  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

• Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call

  8/8/2022

  Kala Pharmaceuticals, Inc. today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022.

• Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August 2022

  8/4/2022

  Kala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, announced that management will participate in the following virtual healthcare investor conferences in August 2022:

• Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - July 22, 2022

  7/22/2022

  Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

• Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

  7/11/2022

  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, announced today that it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was announced on May 23, 2022.

• Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - June 17, 2022

  6/17/2022

  Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

• Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

  6/2/2022

  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies Healthcare Conference in New York, NY. Members from the management team are scheduled to participate in a fireside chat on Thursday, June 9, 2022 at 10:30 a.m. ET.

• Alcon to Acquire EYSUVIS Adding to Its Ophthalmic Eye Drop Portfolio

  5/23/2022

  Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced it has signed an agreement to acquire EYSUVIS® 0.25% pharmaceutical eye drops from Kala Pharmaceuticals, Inc.

• Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

  5/23/2022

  Kala Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to sell its commercial portfolio and related intellectual property assets to Alcon Inc.

• Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

  5/16/2022

  Kala Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

• Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

  5/9/2022

  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2022 financial results on Monday, May 16, 2022.

• Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®

  5/3/2022

  Kala Pharmaceuticals, Inc., today announced that the largest Pharmacy Benefit Manager in the United States has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 1, 2022.

• Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

  5/1/2022

  Kala Pharmaceuticals, Inc. reported clinical data from a Phase 1b trial of KPI-012, its novel, cell-free secretome therapy for the treatment of severe ocular diseases driven by impaired healing.